Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Tax Provisions (2017 - 2025)

Avalo Therapeutics filings provide 9 years of Tax Provisions readings, the most recent being $130000.0 for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 14.04% to $130000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $165000.0, a 44.74% increase, with the full-year FY2025 number at $165000.0, up 44.74% from a year prior.
  • Tax Provisions hit $130000.0 in Q4 2025 for Avalo Therapeutics, up from $11000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $130000.0 in Q4 2025 to a low of -$200000.0 in Q2 2021.
  • Median Tax Provisions over the past 5 years was $8000.0 (2022), compared with a mean of $6052.6.
  • The widest YoY moves for Tax Provisions: up 1366.67% in 2024, down 275.0% in 2024.
  • Avalo Therapeutics' Tax Provisions stood at -$16000.0 in 2021, then surged by 150.0% to $8000.0 in 2022, then plummeted by 212.5% to -$9000.0 in 2023, then surged by 1366.67% to $114000.0 in 2024, then grew by 14.04% to $130000.0 in 2025.
  • The last three reported values for Tax Provisions were $130000.0 (Q4 2025), $11000.0 (Q3 2025), and $16000.0 (Q2 2025) per Business Quant data.